Literature DB >> 24657195

The alternative splicing side of cancer.

Giuseppe Biamonti1, Morena Catillo2, Daniela Pignataro2, Alessandra Montecucco2, Claudia Ghigna2.   

Abstract

Alternative splicing emerges as a potent and pervasive mechanism of gene expression regulation that expands the coding capacity of the genome and forms an intermediate layer of regulation between transcriptional and post-translational networks. Indeed, alternative splicing occupies a pivotal position in developmental programs and in the cell response to external and internal stimuli. Not surprisingly, therefore, its deregulation frequently leads to human disease. In this review we provide an updated overview of the impact of alternative splicing on tumorigenesis. Moreover, we discuss the intricacy of the reciprocal interactions between alternative splicing programs and signal transduction pathways, which appear to be crucially linked to cancer progression in response to the tumor microenvironment. Finally, we focus on the recently described interplay between splicing and chromatin organization which is expected to shed new lights into gene expression regulation in normal and cancer cells.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alternative splicing; Epigenetic; Epithelial to mesenchymal transition; Signal transduction; Splicing factors

Mesh:

Substances:

Year:  2014        PMID: 24657195     DOI: 10.1016/j.semcdb.2014.03.016

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  51 in total

Review 1.  The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.

Authors:  Elisabeth Daguenet; Gwendal Dujardin; Juan Valcárcel
Journal:  EMBO Rep       Date:  2015-11-13       Impact factor: 8.807

Review 2.  Alternative splicing as a biomarker and potential target for drug discovery.

Authors:  Kai-qin Le; Bellur S Prabhakar; Wan-jin Hong; Liang-cheng Li
Journal:  Acta Pharmacol Sin       Date:  2015-06-15       Impact factor: 6.150

3.  UXT-AS1-induced alternative splicing of UXT is associated with tumor progression in colorectal cancer.

Authors:  Jun Yin; Wei Luo; Xiang Zeng; Lisi Zeng; Zhiyang Li; Xiaofang Deng; Xiaojun Tan; Weimin Hu
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

4.  Modulators of alternative splicing as novel therapeutics in cancer.

Authors:  Sebastian Oltean
Journal:  World J Clin Oncol       Date:  2015-10-10

Review 5.  Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.

Authors:  Nidhi Jyotsana; Michael Heuser
Journal:  Expert Opin Ther Targets       Date:  2017-12-20       Impact factor: 6.902

6.  Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44.

Authors:  Tadas K Rimkus; Richard L Carpenter; Sherona Sirkisoon; Dongqin Zhu; Boris C Pasche; Michael D Chan; Glenn J Lesser; Stephen B Tatter; Kounosuke Watabe; Waldemar Debinski; Hui-Wen Lo
Journal:  Cancer Res       Date:  2018-02-20       Impact factor: 12.701

7.  A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer.

Authors:  Fernando J de Miguel; María J Pajares; Elena Martínez-Terroba; Daniel Ajona; Xabier Morales; Ravi D Sharma; Francisco J Pardo; Ana Rouzaut; Angel Rubio; Luis M Montuenga; Ruben Pio
Journal:  Mol Oncol       Date:  2016-08-09       Impact factor: 6.603

8.  Alternative splicing of S6K1 promotes non-small cell lung cancer survival.

Authors:  Hong Mei; Ye Wang; Jiquan Fan; Zhenyu Lin
Journal:  Tumour Biol       Date:  2016-07-27

Review 9.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

Review 10.  Alternative Splicing in CKD.

Authors:  Megan Stevens; Sebastian Oltean
Journal:  J Am Soc Nephrol       Date:  2016-01-13       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.